<DOC>
	<DOCNO>NCT00476645</DOCNO>
	<brief_summary>The purpose study determine treatment fulvestrant lead slow tumor progression patient develop androgen-independent ( AIPC ) hormone-refractory prostate cancer ( HRPC ) rise serum prostate specific antigen ( PSA ) .</brief_summary>
	<brief_title>Fulvestrant Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description>The purpose study determine treatment fulvestrant lead slow tumor progression patient develop androgen-independent ( AIPC ) hormone-refractory prostate cancer ( HRPC ) rise serum prostate specific antigen ( PSA ) . In vitro study show fulvestrant downregulates androgen receptor ( AR ) LNCaP cancer cell line significant extent , thereby inhibit growth tumor cell . In addition , important emphasize fulvestrant also find decrease growth AR-negative prostate cancer cell . These observation provide rational use fulvestrant treatment AIPC HRPC .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Must give sign write informed consent Must age 18 year old Histologically confirm adenocarcinoma prostate Must currently receive LHRH agonist castrate level testosterone orchiectomy Must rise PSA despite antiandrogen withdrawal Must exhibit two consecutive rise PSA last hormonal manipulation Minimum PSA &gt; 5mg/dL KPS &gt; 80 % Up one prior chemotherapy treatment allow Life expectancy great 6 month Concomitant hormonal therapy LHRH Noncompliance Platelets le 100 x 10e9 /L International normalization ratio ( INR ) great 1.6 Total bilirubin great 1.5 x ULRR ALT AST great 2.5 x ULRR demonstrable liver metastasis great 5.0 x ULRR presence liver metastases History bleed diathesis ( ie , disseminate intravascular coagulation [ DIC ] , clot factor deficiency ) History longterm anticoagulant therapy ( antiplatelet therapy ) History hypersensitivity active inactive excipients fulvestrant ( ie , castor oil Mannitol )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>